Galectin Therapeutics Inc. Common Stock (GALT) Director James C. Czirr Sells 208,140 Shares

Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT) Director James C. Czirr sold 208,140 shares of the company’s stock in a transaction on Wednesday, June 13th. The stock was sold at an average price of $7.17, for a total transaction of $1,492,363.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of Galectin Therapeutics Inc. Common Stock stock traded up $0.33 during trading on Thursday, hitting $8.15. The company’s stock had a trading volume of 3,094,227 shares, compared to its average volume of 692,425. The firm has a market cap of $224.67 million, a price-to-earnings ratio of -16.63 and a beta of 2.70. Galectin Therapeutics Inc. Common Stock has a 52 week low of $1.28 and a 52 week high of $8.56.

Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT) last issued its quarterly earnings results on Friday, May 11th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.01. equities analysts anticipate that Galectin Therapeutics Inc. Common Stock will post -0.5 EPS for the current fiscal year.



Several research analysts have commented on the stock. ValuEngine upgraded shares of Galectin Therapeutics Inc. Common Stock from a “hold” rating to a “buy” rating in a report on Friday, June 1st. HC Wainwright increased their price target on shares of Galectin Therapeutics Inc. Common Stock to $12.00 and gave the stock a “buy” rating in a research note on Tuesday, May 15th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $6.94.

Institutional investors have recently modified their holdings of the stock. Wedbush Securities Inc. bought a new position in shares of Galectin Therapeutics Inc. Common Stock in the 4th quarter worth about $102,000. Benchmark Capital Advisors increased its stake in shares of Galectin Therapeutics Inc. Common Stock by 19.7% in the 1st quarter. Benchmark Capital Advisors now owns 221,700 shares of the company’s stock worth $1,051,000 after acquiring an additional 36,500 shares in the last quarter. D.A. Davidson & CO. increased its stake in shares of Galectin Therapeutics Inc. Common Stock by 6.3% in the 1st quarter. D.A. Davidson & CO. now owns 731,300 shares of the company’s stock worth $3,466,000 after acquiring an additional 43,147 shares in the last quarter. Millennium Management LLC bought a new position in shares of Galectin Therapeutics Inc. Common Stock in the 1st quarter worth about $454,000. Finally, LPL Financial LLC bought a new position in shares of Galectin Therapeutics Inc. Common Stock in the 1st quarter worth about $112,000. Institutional investors own 13.16% of the company’s stock.

About Galectin Therapeutics Inc. Common Stock

Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company's lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer.

Insider Buying and Selling by Quarter for Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT)

Receive News & Ratings for Galectin Therapeutics Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply